- Home
- MDAI vs ELOX Comparison
MDAI vs ELOX Comparison
Compare MDAI & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDAI | ELOX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.5M | 41.0M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MDAI | ELOX |
|---|---|---|
| Price | $1.57 | $15.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 142.2K | 36.2K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.88 | 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,650,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.18 | $10.00 |
| 52 Week High | $2.97 | $23.40 |
Technical Indicators
Market Signals| Indicator | MDAI | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 41.25 |
| Support Level | $1.49 | $10.74 |
| Resistance Level | $1.77 | $14.37 |
| Average True Range (ATR) | 0.06 | 2.62 |
| MACD | -0.00 | -0.67 |
| Stochastic Oscillator | 8.62 | 2.95 |
Price Performance
Historical ComparisonAbout MDAI Spectral AI Inc.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.
About ELOX Eloxx Pharmaceuticals Inc. Common Stock
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.